Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Cesium carbonate → 2-[3-(3-Fluoro-4-morpholin-4-yl-piperidin-1-yl)-phenyl]-1-methyl-1H-benzoimidazole
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Cesium carbonate | HCID 10796 | — |
| 반응물 | Binap, (A+-)- | HCID 634876 | — |
| 반응물 | 2-(3-bromophenyl)-1-methyl-1H-benzimidazole | HCID 962451 | — |
| 반응물 | 4-(3-Fluoro-piperidin-4-yl)-morpholine | HCID 68670746 | — |
| 촉매 | palladium(II) acetate | HCID 167845 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | 2-[3-(3-Fluoro-4-morpholin-4-yl-piperidin-1-yl)-phenyl]-1-methyl-1H-benzoimidazole | HCID 68671327 | — |
반응 단계
4-(3-Fluoro-piperidin-4-yl)-morpholine (0.085 g, 0.45 mmol), 2-(3-Bromo-phenyl)-1-methyl-1H-benzoimidazole (described in method N, step a, b) (0.10 g, 0.35 mmol), and cesium carbonate (10.50 g, 32.2 mmol) were placed into a dry sealed 7 mL vial under nitrogen and dry toluene (0.4 mL) was added. At the same time Palladium acetate (0.016 g, 0.07 mmol), and BINAP (0.065 g, 0.10 mmol) were placed into another dry sealed 7 mL vial under nitrogen and diluted with dry toluene (0.8 mL) After about 20 minutes the resulting suspension was added to the vial containing the starting materials.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08592463B2 |
| 출처 데이터셋 | uspto-grants-2013_11 |
| ORD ID | ord-639d0b6d540e4f4bafe23bf639e62468 |
| 출처 메모 | uspto-grants-2013_11 |